Novartis Ag

Viatris Gmbh & Co Kg

Matthias Olbrich

Rainer Gewald

Heinrich Potter

The invention relates to a process for the production of (R)- or (S)-8-chloro-6-hydroxyoctanoic acid alkyl esters of the general formula (R)-II or (S)-II, in which R means Calkyl, from 8-chloro-6-oxo-octanoic acid alkyl esters of the general formula I, in which R has the above meaning. The desired enantiomers are produced biocatalytically in an enantioselective reduction, wherein as desired the strains Mucor racemosus are used for (S)-II compounds and Geotrichum candidum for (R)-II compounds. The resultant esters may, in known manner, be converted stereospecifically into (R)-&#x3b1;-lipoic acid.

Process for the enantioselective reduction of 8-chloro-6-oxo-octanoic acid alkyl esters

The invention relates to formulations of cyclosporin with high bioavailability for oral administration, which contain about 1 part by weight of one or more cyclosporin(s), preferably cyclosporin A and/or cyclosporin G, 7.5 to 7.8 parts by weight of one or more polyethylene glycol esters of saturated C -C hydroxy fatty acids, 0.7 to 0.85 part by weight of a monohydric alcohol as co-solvent, and 0.7 to 0.8 part by weight of a polyhydric alcohol as co-solvent. The drug form is produced by initially dissolving the cyclosporin in ethanol and, while stirring, adding propylene glycol and SOLUTOL&reg; HS 15 until a clear, viscous solution results, bottled as drinkable solution or packed into capsules.

Growing community of inventors

Reichenberg, Germany

Matthias Olbrich